Omeprazol Sun (Omeprazole)

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions:

• Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease: accelerates ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.
• Helicobacter pylori eradication regimens: used as adjunct therapy to improve eradication rates when combined with antibiotics.
• NSA‑induced ulcer prophylaxis: lowers the risk of ulcer formation in patients requiring long‑term NSAID therapy.

• Omeprazole irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells, inhibiting the final step of acid secretion. By blocking this pump, it markedly reduces both basal and stimulated gastric acid output, allowing mucosal healing and symptom relief in acid‑related disorders.

Adverse reactions to omeprazole may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually self‑limiting.
• Nausea or abdominal discomfort.
• Flatulence or bloating.
• Constipation.
• Dry mouth.

Serious or Rare Side Effects

• Severe allergic reactions (anaphylaxis, angioedema).
• Clostridioides difficile‑associated colitis.
• Low magnesium levels (hypomagnesemia) with prolonged use.
• Bone fractures (hip, wrist, spine) linked to long‑term therapy.
• Interstitial nephritis.
• Liver enzyme elevations indicating possible hepatitis.

When prescribing omeprazole, clinicians should consider several safety aspects:

• Assess renal and hepatic function: dose adjustment may be needed in severe impairment.
• Review long‑term use: prolonged therapy is associated with increased fracture risk and nutrient malabsorption.
• Monitor for infections: reduced gastric acidity can predispose to gastrointestinal infections.
• Evaluate concomitant medications: potential for drug‑drug interactions, especially with drugs requiring acidic pH for absorption.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: omeprazole reduces its antiplatelet activation, diminishing efficacy.
• Atazanavir and other protease inhibitors: decreased absorption due to higher gastric pH.
• Methotrexate (high dose): increased serum levels and toxicity risk.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Digoxin: higher plasma concentrations possible; monitor levels.
• Diazepam and other benzodiazepines: increased sedation; adjust dosing if needed.
• Iron salts: reduced absorption; separate administration by at least 2 hours.
• Vitamin B12 supplements: decreased absorption with chronic use; monitor status.